These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. [Combined thrombolysis by pharmacokinetically different plasminogen activators]. Maksimenko AV Bioorg Khim; 1998 May; 24(5):376-80. PubMed ID: 9661792 [TBL] [Abstract][Full Text] [Related]
45. Thrombolysis for restoration of patency to haemodialysis central venous catheters: a systematic review. Clase CM; Crowther MA; Ingram AJ; Cinà CS J Thromb Thrombolysis; 2001 Apr; 11(2):127-36. PubMed ID: 11406727 [TBL] [Abstract][Full Text] [Related]
46. The influence of transport parameters and enzyme kinetics of the fibrinolytic system on thrombolysis: mathematical modelling of two idealised cases. Zidansek A; Blinc A Thromb Haemost; 1991 May; 65(5):553-9. PubMed ID: 1831302 [TBL] [Abstract][Full Text] [Related]
47. Suppression of argatroban-induced endogenous thrombolysis by PKSI-527, and antibodies to TPA and UPA, evaluated in a rat arterial thrombolysis model. Hashimoto M; Oiwa K; Matsuo O; Ueshima S; Okada K; Okada Y; Okamoto S; Giddings JC; Yamamoto J Thromb Haemost; 2003 May; 89(5):820-5. PubMed ID: 12719778 [TBL] [Abstract][Full Text] [Related]
48. [Arterial thrombolysis. Review and future prospects]. Marzelle J; Combe S; Gigou F; Samama M J Mal Vasc; 1988; 13(4):307-16. PubMed ID: 3143794 [TBL] [Abstract][Full Text] [Related]
49. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia. Sauls DL; Lockhart E; Warren ME; Lenkowski A; Wilhelm SE; Hoffman M Biochemistry; 2006 Feb; 45(8):2480-7. PubMed ID: 16489740 [TBL] [Abstract][Full Text] [Related]
50. Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing liposomes in rabbits: a comparison with free t-PA. Heeremans JL; Prevost R; Bekkers ME; Los P; Emeis JJ; Kluft C; Crommelin DJ Thromb Haemost; 1995 Mar; 73(3):488-94. PubMed ID: 7667833 [TBL] [Abstract][Full Text] [Related]
51. Resistance of porcine blood clots to lysis relates to poor activation of porcine plasminogen by tissue plasminogen activator. Flight SM; Masci PP; Lavin MF; Gaffney PJ Blood Coagul Fibrinolysis; 2006 Jul; 17(5):417-20. PubMed ID: 16788320 [TBL] [Abstract][Full Text] [Related]
52. Staphylokinase reduces plasmin formation by endogenous plasminogen activators. Jin T; Bokarewa M; Zhu Y; Tarkowski A Eur J Haematol; 2008 Jul; 81(1):8-17. PubMed ID: 18331597 [TBL] [Abstract][Full Text] [Related]
57. Comparison of local thrombolytic efficacy of plasmin and rt-PA in an in-vitro flow system; a pilot study. Bizjak N; Bajd F; Vidmar J; Blinc A; Marder VJ; Novokhatny V; Serša I Blood Coagul Fibrinolysis; 2013 Oct; 24(7):711-4. PubMed ID: 23751605 [TBL] [Abstract][Full Text] [Related]
58. A long-lasting, plasmin-activatable thrombin inhibitor aids clot lysis in vitro and does not promote bleeding in vivo. Sheffield WP; Eltringham-Smith LJ; Gataiance S; Bhakta V Thromb Haemost; 2009 May; 101(5):867-77. PubMed ID: 19404540 [TBL] [Abstract][Full Text] [Related]
59. Evidence for a role of the plasminogen activator--plasmin system in corneal ulceration. Berman M; Leary R; Gage J Invest Ophthalmol Vis Sci; 1980 Oct; 19(10):1204-21. PubMed ID: 6252112 [TBL] [Abstract][Full Text] [Related]